CRVS · Insider Trading
Corvus Pharmaceuticals, Inc.
Every open-market purchase and sale reported by CRVS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Ian T Clark | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Linda Grais | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Broek Richard van den | Director | A | +15,000 deriv. | — |
| 2026-06-15 | Peter A. Thompson | Director | A | +15,000 deriv. | — |
| 2026-06-15 | David Scott Moore | Director | Buy | +21,700 | +$250.24K |
| 2026-05-20 | Richard A Md Miller | President and CEO | Buy | +6,932 | +$83.45K |
| 2026-04-27 | Andrew C. Chan | Director | A | +30,000 deriv. | — |
| 2026-01-30 | Peter A. Thompson | Director | M | +210,000 | +$1.12M |
| 2025-12-08 | William Benton Jones | See Remarks | A | +400,000 deriv. | — |
| 2025-12-08 | Jeffrey Arcara | Chief Business Officer | A | +100,000 deriv. | — |
| 2025-12-08 | Richard A Md Miller | President and CEO | A | +1,000,000 deriv. | — |
| 2025-12-08 | Leiv Lea | Chief Financial Officer | A | +400,000 deriv. | — |
| 2025-10-06 | David Scott Moore | Director | A | +30,000 deriv. | — |
| 2025-07-01 | OrbiMed Capital GP V LLC | Director | MIXED | +442,704 | −$1 |
| 2025-07-01 | Peter A. Thompson | Director | MIXED | +221,352 | −$0 |
| 2025-06-16 | Peter A. Thompson | Director | A | +15,000 deriv. | — |
| 2025-06-16 | Linda Grais | Director | A | +15,000 deriv. | — |
| 2025-06-16 | Scott W Morrison | Director | A | +15,000 deriv. | — |
| 2025-06-16 | Ian T Clark | Director | A | +15,000 deriv. | — |
| 2025-06-06 | William Benton Jones | See Remarks | M | +19,357 | +$67.75K |
| 2025-05-09 | Richard A Md Miller | President and CEO | M | +559,073 | +$1.96M |
| 2025-04-09 | Broek Richard van den | Director | A | +30,000 deriv. | — |
| 2024-12-23 | William Benton Jones | See Remarks | A | +300,000 deriv. | — |
| 2024-12-23 | Richard A Md Miller | President and CEO | A | +750,000 deriv. | — |
| 2024-12-23 | Jeffrey Arcara | Chief Business Officer | A | +50,000 deriv. | — |
| 2024-12-23 | Leiv Lea | Chief Financial Officer | A | +300,000 deriv. | — |
| 2024-06-17 | Linda Grais | Director | A | +15,000 deriv. | — |
| 2024-06-17 | Ian T Clark | Director | A | +15,000 deriv. | — |
| 2024-06-17 | Scott W Morrison | Director | A | +15,000 deriv. | — |
| 2024-06-17 | Terry P Gould | Director | A | — | — |
| 2024-06-17 | Peter A. Thompson | Director | A | — | — |
| 2024-05-14 | Richard A Md Miller | President and CEO | G | −302,016 | — |
| 2024-05-08 | Peter A. Thompson | Director | Buy | +2,841,769 deriv. | — |
| 2024-05-08 | OrbiMed Capital GP V LLC | Director | Buy | +5,683,538 deriv. | — |
| 2024-05-07 | Richard A Md Miller | President and CEO | Buy | +577,634 | +$1000.00K |
| 2024-05-07 | William Benton Jones | See Remarks | Buy | +20,000 | +$34.62K |
| 2024-03-01 | Jeffrey Arcara | Chief Business Officer | A | +400,000 deriv. | — |
| 2023-12-08 | Leiv Lea | Chief Financial Officer | A | +200,000 deriv. | — |
| 2023-12-08 | Terry P Gould | Director | A | — | — |
| 2023-12-08 | William Benton Jones | See Remarks | A | +200,000 deriv. | — |
| 2023-12-08 | Ian T Clark | Director | A | +15,000 deriv. | — |
| 2023-12-08 | Peter A. Thompson | Director | A | — | — |
| 2023-12-08 | Linda Grais | Director | A | +15,000 deriv. | — |
| 2023-12-08 | Edith P. Mitchell | Director | A | +15,000 deriv. | — |
| 2023-12-08 | Scott W Morrison | Director | A | +15,000 deriv. | — |
| 2023-12-08 | Richard A Md Miller | President and CEO | A | +500,000 deriv. | — |
| 2023-06-20 | Scott W Morrison | Director | A | +15,000 deriv. | — |
| 2023-06-20 | Linda Grais | Director | A | +15,000 deriv. | — |
| 2023-06-20 | Ian T Clark | Director | A | +15,000 deriv. | — |
| 2023-06-20 | Peter A. Thompson | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Peter A. Thompson | Director | 8,684,091 | $89.53M |
| OrbiMed Capital GP V LLC | Director | 8,341,338 | $86.00M |
| Richard A Md Miller | President and CEO | 2,329,810 | $24.02M |
| William Benton Jones | See Remarks | 173,130 | $1.78M |
| Leiv Lea | Chief Financial Officer | 133,238 | $1.37M |
| David Scott Moore | Director | 21,700 | $223.73K |
| Linda Grais | Director | 10,000 | $103.10K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRVS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.